The fifth China International Import Expo, kicking off on Saturday, is offering great opportunities for internationally leading pharmaceutical company Gilead Sciences to showcase its new discoveries in virology, oncology and mycology sciences, the company said.

This year marks the 35th anniversary of Gilead Sciences' establishment. With the vision of "creating a healthier world", the company has been committed to promoting drug innovation in a bid to treat diseases such as HIV, viral hepatitis and cancer.

At its booth during the fair, the company is exhibiting a group of new launches in China, looking forward to setting up more partnerships to improve new drug accessibility and eliminate barriers for the public to pursue their well-being and health, and promote the construction of the " Healthy China 2030" initiative with joint efforts.

Gilead Sciences launched China operations in 2017 in Shanghai. In recent years, it has grown from zero to a large-scale company with more than 600 employees. Nine of its products have been launched in the Chinese market and seven of them have entered the national reimbursement drug list. It has launched businesses across more than 80 cities in China.

The CIIE is an excellent platform for a company to expand the opening-up scale, set up cooperative partnerships and achieve win-win results, the company said.

The company is tapping into the field of oncology and mycology in China. So this is a good time to show their past achievements and more importantly, their future development plans, the company said.

"To further help address the health challenges faced by the people and communities, we need more than just drugs," said Jim Jin, vice-president of the company and general manager of its China arm.

"Therefore, we won't stop at science, but instead hold out hope that our innovative products can benefit more patients through continuous efforts in removing the barriers in the medical service process."

Gilead plans to sign a strategic cooperation memorandum with Hainan Lecheng during the expo, jointly promoting the implementation of more innovative products and diagnostic and treatment programs urgently needed in the clinical field in Lecheng pilot area.

Gilead is an innovation-driven company deeply rooted in scientific research and development. With its commitment to breaking through impossibilities, it has been pursuing new therapies, and solving the problems of disease treatment.

As part of its efforts to improve R&D capability in China, the company is planning to recruit more talent and include more Chinese patients in its global clinical trials.

In response to the national action plan for the prevention and control of viral hepatitis, Gilead will sign a three-year strategic cooperation project to support the national action plan and eliminate the public health hazards of hepatitis C. It will do so with the Chinese Association of STD and AIDS Prevention and Control during the expo.

"Whether it is about the introduction of innovative products or the expansion of product lineup, every expansion of Gilead in China will adhere to its original intention and commitment of patient-centered action," Jin said.

"With the willingness to cultivate China with in-depth effort, we very much hope to accelerate the introduction of innovative products through the platform of the CIIE, to provide more and better innovative products for Chinese patients," Jin added.